Genetic Technologies Investor Presentation September 2022

Genetic Technologies
Business Update
September 8, 2022
Authorised by the Board of Directors of Genetic Technologies Limited
ASX: GTG
NASDAQ: GENE

Notice: Forward looking statements
The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328
(ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require
further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with
past and future announcements made by the Company and should not be relied upon as an independent source of information. Please
refer to the Company’s website and/or the Company’s filings to the ASX and SEC for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been independently
verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking
statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the
current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of
which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or
expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially
to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all
forward looking statements contained in this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be
construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
2

Vision and World Leading Portfolio
Our Overview
Markets & Global Presence
Expansion to over 40 countries with a multi brand strategy
Focus Areas and Market Opportunity
Financial and Strategic highlights
Pathways to Market
Cutting edge technology
Patented Innovation and Divisions
Brand segmentation and distribution channels
3
Unlocking personalised preventative health
Key Operating Insights
Seizing a Multi-billion dollar opportunity

Unlocking personalised
preventative medicine
Genetic Technologies has the most comprehensive
and guideline driven portfolio. Transforming the
conversation from a one-size-fits-all model to
personalised, preventive health
Where each person has the information, they need
to manage their health according to their own risk.
Empowering physicians to improve health
outcomes for people around the world.
Tracking disease to its source and enabling a
new era of personalised medicine.
4

5
Most comprehensive guideline driven
portfolio for human and animal health.
• Patented GeneType Multi Risk Test
• Non-Invasive Prenatal Testing (NIPT)
• Carrier screen testing
• Pharmacogenomics
• Oncogenetic diseases
• Pet care
Revenues anchored by our 3 brands to seize
a multi Billion-dollar opportunity.
World leading portfolio
5

6
Genetype tests integrate individual’s familial, clinical and
genetic information into actionable clinical insights.
Combining genetic and clinical risk models with cutting-edge
research, we’re leading a personalised healthcare revolution.
Our medical practitioners, scientists and technicians have
developed the next generation of integrated predictive
genetic testing and assessment tools – empowering
physicians and patients to proactively manage health.
Patented* integrated risk
testing for a range of
critical medical conditions
✓ 10 Patent families covering the GeneType products
✓ 4 Patents granted in the US
✓ 2 Patents granted in China
✓ 9 Patents pending Worldwide
* Patents granted are specific to the GeneType portfolio of products

7
Unequalled
experience
Scientific team leveraging their
extensive research track record
in breast and colorectal to
expand our medical-grade
genetic test portfolio into further
cancers and chronic conditions.
Relentless
innovation
Accelerating the world’s
transition to personalised,
preventative health care by
converting genetic data into
actionable solutions for
consumers and doctors.
Leading
integrated
technology
The proprietary integration of
genomic and clinical risk factors
delivers the most complete risk
assessments for serious
diseases in the world –
the foundation of geneType.
Setting new
standards
Setting clinical, safety and
ethical standards to ensure
the best health outcomes.

Global Overview
57
Employees
globally
40
Countries
25
Patents
Granted*
(9 Pending
Worldwide*)
14
Test
Categories
51
Tests
12
Partner
Laboratories
8

half-year ending December
31, 2021
Delivering Revenue and Growth June Qtr FY22
$68
$2,013
$89
$6,789
Q4 FY21 Q4 FY22 YTD Jun FY21 YTD Jun FY22#
Cash Receipts (A$'000)
Strategic & Operational Highlights:
• Full year receipts from customers A$6.8m with 4 consecutive qtrs. of growth on prior year
• Completed independently developed Budget Impact Model (BIM) demonstrating US$1.4b in potential savings for US payers annually
• Initiated discussions with national payers in the US for GeneType risk tests
• GeneType Multi-Risk Test is implemented in 24 clinics building our geneType hub strategy
• EasyDNA entered the European market with carrier testing and Non-Invasive Prenatal Test (NIPT) and launches DNA storage strategy
• EasyDNA entered India’s equine industry with stud farm partnerships broadening its paternity infrastructure
• Successful ARTG notification to TGA for company IVDs for all test on the Multi-Risk test
REVENUE
A$2.01m
GROSS MARGIN
A$1.0m
GROSS MARGIN
51%
9
CASH BALANCE
A$11.7m*
*June ’22 quarter end cash and cash equivalents of A$11.7 million
# All revenues for 2021 - 2022 are 'out of pocket' our strategy for reimbursement should become effective in 2022 - 2023 FY

Commercialisation of the geneType suite of multi-risk tests
Our FOCUS
Core ‘4’
Commercialisation of the geneType suite of multi-risk tests
Demonstrate clinical validity & clinical utility of geneType tests
Innovation: Next Generation of capability – Starting with Epigenetics
EasyDNA & Affinity DNA Revenue Growth: Tests, Channels. & Markets
Execute the B2B commercialisation of the geneType multi-risk test
10

Market Size and Opportunity
Estimated Global Revenue growth is US$2.8B in to 2025
11
2.60
2.01
1.22
0.76
CAGR
16.3%
Growth
$1.3B
CAGR
18.1%
Growth
$1.4B
Predictive Genomics1
Direct to Consumer2
1. Newsire - Predictive Genetics Market Research Report by Type, by Demographics, by Test Type January 6 2022
2. Technavio Market Research reports - Direct-To-Consumer Genetic Testing Market by Distribution Channel, Service, and Geography - Forecast and Analysis 2021-2025
2025
2020
US$ ’Billion US$ ’Billion

[insert revenue structure and agreement
types]
Product list
Our Innovation – Multi-Risk Test
GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment.
GeneType Risk assessment test for breast cancer has demonstrated improved early stage
detection by 18% and saving approx. US$1.4B per annum4 for the US payer
12
NEW Universal sample collection kit with
TGA, FDA and EU regulatory approval1
GeneType Multi-
test covers
>70% of mortality
& morbidity
Phase 1 Launch 2 Phase 2 Launch 3
1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
2. Commercial availability expected Q1 CY2022
3. Commercial availability upon regulatory approval
4. Budget Impact Model prepared by Alva10
Breast Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Pancreatic Cancer
Ovarian Cancer
Oncology Cardiovascular
Atrial Fibrillation
Coronary Artery
Disease
Metabolic
Type 2 Diabetes
Diseases Areas

Economic Modeling in the US Payer System1
The economic benefit to the payers in the US is US$1.4B per annum
$73
US Payor system
will save per
patient per year
69% - 74%
overall increase in
women getting
screened
6.8%-9.2%
Supplemental
screening frequency
14.8% - 8.8%
Interval Cancers
drop
57% - 67%
Early-stage cancer
detection
1 Corporates and Insurance market entry assessment - Health Economic Model completed by ALVA10 May 2022.
3.6% in annual savings to a payer system in the screening and treatment of
breast cancer.
13

BC = Breast Cancer; CRC = Colorectal Cancer; PC = Prostate Cancer; CVD = Cardiovascular Disease; IHD = Ischemic Heart Disease; Atrial Fibrillation
1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
NEW Universal sample collection kit with
TGA, FDA and EU regulatory approval1
Divisions of Operations
Emerging divisions
Lifestyle
Ancestry and
Microbiome
Oncology
BC, CRC, PC,
Melanoma
Metabolic
diseases
Diabetes
Pharmoco-
Genetics &
Taliaz
Companion
diagnostics
Germline
testing
BRCA, Lynch
Syndrome and
Somatic testing
Carrier Testing
NIPT &
Reproductive
carrier
screening
CVD
(Heart Disease)
IHD, AF
COVID-19
Serious disease
risk (SDR)
Existing divisions Universal
collection test kit
to support Multi
Test Launch
NEW
14

[insert revenue structure
and agreement types]
Product list
Product list
15
Pathways to Market
Executing a multi-brand strategy
Direct to Consumer
Testing (DTC)
with no medical supervision
Consumer initiated
testing (CIT)
with medical supervision
Medical & Payer
Business to
Business (B2B)
Oncology – GTG
Cardiovascular
Prenatal NIPT and Carrier testing
Clinical & Molecular
Metabolic
Taliaz Predictix
Expanded Carrier testing & NIPT
Oncology – MultiTest
Cardiovascular – MultiTest
Metabolic – MultiTest
COVID Rick Test
Pharmacogenomics
Product list
Ancestry
Paternity
Health & Wellbeing
Pharmacogenetics
Animal
Drug testing
Relationship
DNA Storage

[insert revenue
structure and
agreement types]
Product list
Medical & Payer
Business to
Business (B2B)
Pathways to Market – highest priority
Health Economic modeling completed by
ALVA10*
Certifying reimbursable testing platform:
BRCA test & LYNCH Syndrome test
A plan curated for: Payers / Insurers*
Primary Care Physicians, Specialists,
Surgeons, Concierge Medicine Groups
geneType Multi-test
BRCA test & LYNCH Syndrome test
Revenue
Drivers
Partners
Products
* Corporates and Insurance market entry assessment in progress and Health Economic Model being completed by ALVA10. 16
Payer coverage is the key driver of revenues for geneType
Coverage from payers in the US will accelerate adoption of geneType Risk
Assessment Tests more widely
Budget Impact Model (BIM) demonstrates significant health & economic
benefits of implementing the geneType Breast Cancer Risk Assessment Test
BIM demonstrated significant economic benefits enabling:
• Direct engagement with a wide range of US payers
• Publication of results in respected peer reviewed journal(s)
US Payers include:
• Humana – 17 million lives covered
• Etna – 22.1 million live covered
• Independence Blue Cross – 3 million lives covered
Smaller payers such as employer groups have potential to move quickly
BIM validates the benefits of implementing geneType

[insert revenue
structure and
agreement types]
Product list
[insert revenue structure and
agreement types]
Product list
Direct to Consumer
Testing (DTC)
with no medical supervision
Consumer initiated
testing (CIT)
with medical supervision
Pathways to Market
Leveraging the EasyDNA brand and
platform provides the foundation to
grow in 40 countries
Agreements with 12 laboratories in North
America, AsiaPac and Europe
EasyDNA paternity, ancestry, gut
microbiome testing and non-medical
related genomic tests
Building consumer awareness of serious
disease test via a platform that integrates
medical supervision
Launched US and Australia CIT platforms
in 2020
Medical partners:
LimsABC
InTeleLabs in the US
Phenix Health in Australia
geneType for Breast Cancer
geneType for Colorectal Cancer
geneType Multi-test
Revenue Drivers
Partners
Products
17

agreement types]
Product list
agreement types]
Product list
PHASE 1
Brand Re-Ignition
Growth strategy for EasyDNA
Brand Refresh
Multi-brand Portfolio
EasyDNA Brand Refresh
Test Rationalization
Website Refresh
Website Development
First-party data collection
Targeted Messaging
Improve User experience and
engagement
PHASE 2
Revenue and Growth Focus
Improved Lead Gen
Google Ads
Facebook Ads
Content & Email Marketing
Influencer Marketing &
Testimonials
New Sales Channels
Amazon store front
Target B2B customer
segments
New Markets
18

GeneType Website – ALL tests LIVE
19

Snapshot and Achievements last 12 months
20
GeneType commercialization
✓ Phase 1 commercial release of the geneType
Multi-Risk test in US
✓ 24 medical practices on-boarded launching
the foundation of geneType Hubs in Australia
✓ Completed 2 Acquisitions – EasyDNA and
AffinityDNA
✓ Presentations by Dr Erika Spaeth at:
✓ San Antonio Breast Cancer Symposium,
✓ Precision Medicines leaders summit
✓ Precision Medicine World Conference
EasyDNA integration activities
✓ Acquisition of EasyDNA completed
✓ Launch Carrier Testing and Non-Invasive
Prenatal Tests (NIPT) into Europe
✓ Partnering in India with stud farms
extending paternity infrastructure into the
equine industry
✓ Launch DNA storage solution in GTG NATA
approved facility
Reimbursement activation
✓ Independently developed Budget Impact
Model (BIM) identifies US$1.4 billion dollars
in annual saving by ALVA 10
✓ Progress on US Payer meetings to enable
coverage across millions of lives
Partnerships
✓ Launch with A/Prof Charles Siles providing
immediate access to more than 1,000
referring primary care physicians and 15,000
patients annually in Australia
✓ Launch of screening for breast cancer risk
with Prof Bruce Mann at Royal Women’s
Hospital in Melbourne
Clinical Validity and IP Strategy
✓ 10 Patents granted
✓ 5 new provisional patents filed
✓ 4 papers published
✓ 3 papers under review
Laboratory Capability
✓ Gained NATA and CMS-CLIA
accreditation and certification for 6
polygenic risk score tests
✓ Successful ARTG notification to TGA for
company IVDs for all tests on the multi-
risk test

Thank you
Investor Relations
Adrian Mulcahy
Market Eye – Automic Group
M: +61 438 630 422
E: adrian.mulcahy@automicgroup.com.au
22
www.linkedin.com/company/genetype-limited
www.genetype.com

BNY Mellon, 69%
Board &
Management ,
6%,
Other, 25%
BNY Mellon Board & Management Other
Top 50 share registry breakdown
Financial Information
Share price (AUD) as at 5 September 2022 0.4c
ADR price (USD) as at 5 September 2022 $1.39
Ord Shares on Issue (M) 9,234
ASX 52-week trading (AUD low/high) 0.3/0.9c
Nasdaq 52-week trading (USD low/high) 0.95/3.54
Market Cap (A$M/US$M) 36.94/22.64
Cash at 30 June 2022 A$11.7m
Cash at 31 March 2022 A$11.4m
Debt (31 March 2022 and 30 June 2022) nil
Dual Listed on the ASX and Nasdaq
Corporate Overview
25

• Net cash inflow of A$197k in Q4 FY’22 (compared to Q3 FY’22
outflow of: A$2.1 million) as we continue to grow EasyDNA and
Affinity DNA brand sales and develop and commercialize our
geneType tests
• Cash reserves of A$11.7 million at 30 June 2022 including the
R&D Tax incentive receipt of A$1.44 million will be directed to:
• Support the commercialization of geneType products
in United States, Europe and Australia
• Develop the direct-to-consumer sales channel through
EasyDNA and AffinityDNA
• US Payer model development for geneType for breast
cancer;
• General product research and development; and
• For general working capital.
A$’000 31-Mar-22 30-Jun-22 Change
Net operating cashflow (2,056) 197 110%
Receipts from customers 1,967 2,013 2%
Research and Development and
Staff costs
1,244 1,429 15%
Cash 11,350 11,733 3%
1 Based on cashflow projections
26
Financial Overview

Dr. Lindsay Wakefield
MBBS
Non – Executive
Director
Mr. Peter Rubinstein
BEc, LLB
Chairman - Non –
Executive Director
Dr. Jerzy “George”
Muchnicki
MBBS
Executive Director
Mr Nick Burrows
B.Com, FAICD, FCA,
FGIA, FTIA, F Fin
Non – Executive
Director
Simon Morriss
GAICD
Chief Executive Officer
Richard Allman
BSc, PhD
Chief Scientific
Officer
Mike Tonroe
BSc, FCA, MAICD
Chief Financial
Officer
Carl Stubbings
Chief Commercial
Officer
Erika Spaeth
PhD
Director of Clinical
Affairs & Medical
Education
Board and Management:
Sales and Scientific expertise leading GTG
27

Professor Jon Emery
MBBCh MA DPhil FRACGP MRCGP
Research & Education Lead,
Primary Care Integration,
Victorian Comprehensive Cancer
Centre Herman Chair of Primary
Care Cancer Research,
University of Melbourne
Professor Finlay Macrae AO
MBBS, MD, FRACP, FRCP, AGAF
MWGO is Principal Fellow and
Professor, Department of
Medicine, University of
Melbourne, and Head of
Colorectal Medicine and
Genetics, The Royal Melbourne
Hospital
Ora K. Gordon, M.D.
MD, MS, FACMG
Regional Medical Director,
Center for Clinical Genetics &
Genomics. Clinical Director, PSJH
Population Health Genomics
Program. Chair, Integrated
Network Cancer Program,
Professor of Genetics, St John
Cancer Institute
Strong Scientific Leadership:
Advisory Board
A.Prof Ron Dick
MBBS, FRACP, FCSANZ,
Chairman of Cardiovascular
Institute at Epworth Healthcare,
an Honorary Cardiologist at the
Alfred Hospital and Bendigo
Healthcare Group.
Completed his MBBS in 1979 and
became a Fellow of the
Australian College of Physicians
in 1986. His interventional
cardiology fellowship was from
the University of Michigan
Medical Centre USA.
28

Product list
29
Collaborations
Professor John
Hopper
Professor Graham
Colditz
Professor Bernard
Rosner
Channing Division of Network Medicine,
Brigham and Women’s Hospital and
Harvard Medical School, Boston,
Massachusetts, USA – Principal
Investigator of the Nurses’ Health Study
(International expert in Biostatistics and
breast cancer epidemiology).
Collaborating on a project to improve
the GeneType Breast Cancer Test and
to Cross-validate the Ovarian cancer
test in the Nurses Health Study
Product list
Deputy Director, Institute for Public
Health. Washington University School
of Medicine, St. Louis, Missouri
(International expert in Biostatistics and
breast cancer epidemiology).
Collaborating on a project to validate
the GeneType for Breast Cancer Test in
African American patients
Product list
Professorial Fellow at the Centre for
Epidemiology and Biostatistics in the
School of Population Global Health,
Melbourne University
Collaborating on a project to improve
the Genetype for Breast Cancer Test
and on a joint project with Prof Emery
to develop clinical utility evidence for
the GeneType tests

Product list
30
Collaborations
Ohio State
University
Memorial Sloane
Kettering Cancer
Professor Jon
Emery
Professor of Primary Care Cancer
Research at the University of
Melbourne, and the Victorian
Comprehensive Cancer Centre
Collaborating on a joint project with
Prof Hopper to develop clinical utility
evidence for the GeneType tests
Product list
Collaborating on a project to
investigate modification of risk in BRCA-
positive patients by polygenic risk
scores [insert revenue structure
Product list
Collaborating on a project to
investigate modification of risk in BRCA-
positive patients by polygenic risk
scores

4 Patents granted in the US
• Patent No: US 11,257,569, Methods of
assessing risk of developing a severe
response to Coronavirus infection
• Patent No: US 11,072,830, Methods for breast
cancer risk assessment
• Patent No: US 10,683,549, Methods for
assessing risk of developing breast cancer
• Patent No: US 10,920,279, Methods for
2 Patents granted in PRC (China & HK)
• Patent No. 201080033130.5 Methods for Breast
Cancer Risk Assessment
• Patent No. 201580063966.2 Methods for
9 Patent families pending
• Breast cancer risk assessment
• Methods for assessing risk of developing prostate cancer
• Methods for assessing risk of developing ovarian cancer
• Methods of assessing risk of developing a severe response to
Coronavirus infection
• Methods of assessing risk of developing a disease
• Methods for assessing risk of developing breast cancer
• Improved methods for assessing risk of developing breast
cancer
• Methods of assessing risk of developing breast cancer
• Methods for assessing risk of developing colorectal cancer
Our Intellectual Property
31

Defined Terms
Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include
cancer and heart disease.
Polygenic risk score - a number associated with one’s disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.
Variant - Single Nucleotide polymorphism (SNP), an alteration in DNA that may be a common or rare event.
Genomic - pertaining to function of genetics from structure to relationship between genetic events.
Genetic - pertaining to a gene.
GWAS - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur
more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint
genetic variations that may contribute to a person’s risk of developing a certain disease.
SNP - Single nucleotide polymorphisms, frequently called SNPs (pronounced “snips”), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a
nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.
Serious Disease Risk (SDR) - Risk associated with acquiring COVID-19 and requiring hospitalisation withs its associated morbidities and mortalities.
Germline Testing – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses
cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.
Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human
samples for diagnostic testing
National Association of Testing Authorities (NATA) - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing
scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of
best practice industry experts for customers who require confidence in the delivery of their products and services.
Next Generation Sequencing (NGS) – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These
technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.
Laboratory Developed Tests (LDT) – A type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.
Consumer Initiated Tests (CIT) - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.
Direct to Consumer (DTC) – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.
Health Care Professionals (HCP) – physician, GP, or specialist authorized to receive the patient results
32

Genetic Technologies Investor Presentation September 2022

More Related Content

Similar to Genetic Technologies Investor Presentation September 2022 (20)

More from RedChip Companies, Inc. (20)

Recently uploaded (20)

Genetic Technologies Investor Presentation September 2022